-+ 0.00%
-+ 0.00%
-+ 0.00%
Abionyx Pharma sees IRIS Pharma 2026 revenue broadly stable vs 2025
Share
Listen to the news
Abionyx Pharma sees IRIS Pharma 2026 revenue broadly stable vs 2025
  • Abionyx forecast IRIS Pharma 2026 revenue broadly stable versus 2025, following S1 2026 consolidated revenue of EUR 1.9 million.
  • Biotech revenue stayed at EUR 0 in S1 2026 as apoA-I bioproduct supply continued free under compassionate access requests.
  • Cash and cash equivalents totaled EUR 26.9 million at June 30, 2026, before receipt of research tax credits and France 2030 aid.
  • Funding runway extended to end-2028, supported by a financing completed in June.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending